Top Markets
#1 Black Phoenix Black Phoenix +355.39%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +62.70%
#4 Akedo Akedo +55.10%
#5 OpenEden OpenEden +54.44%
#6 BasedHype BasedHype +27.45%
#7 Avantis Avantis +21.78%
#8 Cryptopia Cryptopia +21.54%
#9 Acurast Acurast +19.36%
#10 Humanity Humanity +17.48%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rank in Stocks #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Share Price
$0.01292666
Last synced: 2025-04-08
Market Cap
$157.54K
Change (1 day)
6.84%
Change (1 year)
0.00%
Country
GB
Trade Synairgen plc (SNG)

Category

Healthcare
P/B ratio for Synairgen plc (SNG)
P/B ratio as of August 2026 TTM: 0.15
According to Synairgen plc latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0.15. At the end of 2022 the company had a P/B ratio of 0.97.
P/B ratio history for Synairgen plc from 2004 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 0.15 -78.10%
2023 0.69 -29.11%
2022 0.97 -88.10%
2021 8.13 326.23%
2020 1.91 -7.27%
2019 2.06 -99.86%
2018 1.50K 26.76%
2017 1.18K -39.85%
2016 1.97K -1.83%
2015 2.01K -7.72%
2014 2.17K 11,509.79%
2013 18.72 170.50%
2012 6.92 224.88%
2011 2.13 16.99%
2010 1.82 206.96%
2009 0.59 -73.97%
2008 2.28 35.55%
2007 1.68 -99.48%
2006 322.75 18.54%
2005 272.28 1,051.93%
2004 23.64 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 4,043.81%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 4,101.39%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 2,305.03%
BE